Compare CCSI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCSI | CTNM |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.3M | 550.7M |
| IPO Year | 2022 | 2024 |
| Metric | CCSI | CTNM |
|---|---|---|
| Price | $43.00 | $9.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $50.00 | $21.43 |
| AVG Volume (30 Days) | 108.7K | ★ 659.1K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $349,696,000.00 | N/A |
| Revenue This Year | $3.40 | N/A |
| Revenue Next Year | $4.22 | N/A |
| P/E Ratio | $11.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.20 | $6.73 |
| 52 Week High | $45.68 | $17.79 |
| Indicator | CCSI | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 50.10 |
| Support Level | $33.37 | $8.59 |
| Resistance Level | N/A | $13.72 |
| Average True Range (ATR) | 2.06 | 0.81 |
| MACD | 0.67 | 0.30 |
| Stochastic Oscillator | 75.53 | 71.40 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.